Filtered By:
Specialty: Endocrinology
Condition: Diabetes
Therapy: Statin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 41 results found since Jan 2013.

Lower Extremity Peripheral Arterial Disease Is an Independent Predictor of Coronary Heart Disease and Stroke Risks in Patients with Type 2 Diabetes Mellitus in China.
In conclusion, lower extremity PAD increased coronary heart disease and stroke risks in T2DM. PMID: 28607554 [PubMed - in process]
Source: International Journal of Endocrinology - June 14, 2017 Category: Endocrinology Tags: Int J Endocrinol Source Type: research

Myocardial Infarction, Stroke, and All-Cause Mortality According to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study
CONCLUSION: Among the elderly, lower LDL-C was associated with decreased risks of MI and stroke. Lower LDL-C achieved by statins in the elderly was associated with a decreased risk of all-cause death during follow-up, suggesting that LDL-C paradox for the premature death risk in the elderly should not be applied to statin users. Intensive statin therapy should not be hesitated for older adults with cardiovascular risk factors including diabetes.PMID:35255552 | DOI:10.4093/dmj.2021.0225
Source: Diabetes and Metabolism Journal - March 7, 2022 Category: Endocrinology Authors: You-Bin Lee Minji Koo Eunjin Noh Soon Young Hwang Jung A Kim Eun Roh So-Hyeon Hong Kyung Mook Choi Sei Hyun Baik Geum Joon Cho Hye Jin Yoo Source Type: research

Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients.
CONCLUSIONS: High potency lipid-lowering therapy effectively reduces the risk of recurrent IS in diabetic patients regardless of ATOR or EZ-SIM combination therapy. PMID: 27270238 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - June 5, 2016 Category: Endocrinology Authors: Liu CH, Chen TH, Lin MS, Hung MJ, Chung CM, Cherng WJ, Lee TH, Lin YS Tags: J Clin Endocrinol Metab Source Type: research

Stroke in the patient with diabetes (Part 2) -Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes
ConclusionsPCSK9 is inconsistently associated with CV events in populations with T2DM. The association may depend on the level of CV risk and the background treatment
Source: Diabetes, Obesity and Metabolism - December 5, 2017 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, P. Gabriel Steg, Louis Potier, Youmna Ghaleb, S El Bitar, S Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Hadjadj, Catheri Tags: ORIGINAL ARTICLE Source Type: research

Plasma proprotein ‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
ConclusionsWe found that PCSK9 was inconsistently associated with CV events in populations with type 2 diabetes. The association may depend on the level of CV risk and the background treatment.
Source: Diabetes, Obesity and Metabolism - January 14, 2018 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, Philippe Gabriel Steg, Louis Potier, Youmna Ghaleb, Sandy Elbitar, Stephanie Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Tags: ORIGINAL ARTICLE Source Type: research

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute corona...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research

Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial.
CONCLUSIONSIn the ACCORD BP trial, compared with combined standard treatment, intensive BP or intensive glycemia treatment alone improved major CVD outcomes, without additional benefit from combining the two. In the ACCORD lipid trial, neither intensive lipid nor glycemia treatment produced an overall benefit, but intensive glycemia treatment increased mortality. PMID: 24595629 [PubMed - as supplied by publisher]
Source: Diabetes Care - March 4, 2014 Category: Endocrinology Authors: Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH, Lipkin EW, Venkat Narayan KM, Riddle MC, Sood A, Goff DC Tags: Diabetes Care Source Type: research

Regional, age, and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionCV risk factors of TECOS participants are reasonably controlled on average, but differences in CV risk management according to region, sex, and history of prior disease exist. This diversity will enhance generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - January 20, 2015 Category: Endocrinology Authors: M. A. Bethel, J.B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionThe CV risk factors of participants in TECOS are reasonably controlled, but differences in CV risk management according to region, sex and history of disease exist. This diversity will enhance the generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - February 13, 2015 Category: Endocrinology Authors: M. A. Bethel, J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes
CONCLUSIONS This observational study shows that LLT is associated with 22–44% reduction in the risk of CVD and cardiovascular death among individuals with type 1 diabetes without history of CVD and underlines the importance of primary prevention with LLT to reduce cardiovascular risk in type 1 diabetes.
Source: Diabetes Care - May 23, 2016 Category: Endocrinology Authors: Hero, C.; Rawshani, A.; Svensson, A.-M.; Franzen, S.; Eliasson, B.; Eeg-Olofsson, K.; Gudbjörnsdottir, S. Tags: Epidemiology/Health Services Research Source Type: research

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Publication date: Available online 29 July 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Cholesterol Treatment Trialists' (CTT) Collaboration Background Statin therapy is effective for the prevention of coronary heart disease and stroke in patients with mild-to-moderate chronic kidney disease, but its effects in individuals with more advanced disease, particularly those undergoing dialysis, are uncertain. Methods We did a meta-analysis of individual participant data from 28 trials (n=183 419), examining effects of statin-based therapy on major vascular events (major coronary event [non-fatal myoca...
Source: The Lancet Diabetes and Endocrinology - July 28, 2016 Category: Endocrinology Source Type: research